Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The N-terminal Tyrosine protects against enzymatic degradation by aminopeptidases
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
And it's not just about the feeling of energy
Disclaimer This product is intended for laboratory research only and is not for human consumption.
US$ 21.92
US$ 22.55
US$ 24.11
US$ 29.23
